Inventory of China's top ten biochip companies in 2014

Release date: 2014-10-22

Biochips, also known as protein chips or gene chips, originate from the combination of DNA hybrid probe technology and semiconductor industry technology. Biochip technology is a high-throughput detection technology developed in recent years. It uses microelectronics, micromechanics, physical chemistry, and computer technology to construct microfluidic analysis units and systems on the surface of solid chips. Continuous analysis processes (such as sample preparation, chemical reactions, and analytical detection) are continuous, integrated, and miniaturized. Biochips include three major areas: DNA chips, protein chips, and chip labs.

Biochip technology has become the cutting-edge technology of biomedical engineering in the 21st century, and the biochip industry is also growing. The developed countries in the world are rapidly entering the R&D competition of various related industries with biochips as the core. Important academic and industrial institutions in the United States, Britain, Germany, Canada, Russia, Italy, Japan and other countries have invested a large amount of funds and manpower to carry out basic research and application development in this area, and include "biochip" technology in biotechnology. The key development areas have formed a number of related industries.

However, China's biochip research started late, and the research began in 1997-1998. Before that, biochip technology was still blank in China. With the rapid development of chip technology and industry, China has achieved a staged breakthrough from scratch and gradually developed and expanded. Especially during the “10th Five-Year Plan” period, the national “863” program focused on the implementation of the “Functional Genomics and Biochip Research” major project, which provided a slanting support for the development of biochip systems.

At present, the biochip industry has begun to take shape in China and has begun to take shape. It has formed two national engineering research centers in Beijing and Shanghai, and several biochip R&D institutions in Tianjin, Xi'an, Nanjing, Shenzhen and Harbin. A number of biochip companies are booming. Below, the Xiaobian of the OFweek electronic engineering network will take stock of the top ten biochip companies in China in 2014 to attract readers.

Tenth: Nanjing Dayuan Biotechnology Engineering Co., Ltd.

Nanjing Dayuan Biotechnology Engineering Co., Ltd. is located in Pukou Economic and Technological Development Zone, Nanjing City, Jiangsu Province. It is invested by US Great Oceans Engineering Co., Ltd. under the Taiyuan International Group in 2000. It invests US$1,000,000 in high-tech agriculture. Development and application, research and development of gene chips and pharmaceutical technology, and later due to mature research and development technology, officially entered the mass production stage. In October 2002, the company invested again by Singapore Dayuan Engineering Co., Ltd., and the company increased its capital to US$2,000,000. Engaged in high-tech biochips, biochip identification devices, biochip analyzers, related testing reagents, consumables, medical devices, related antigens, antibodies, proteins and other production and sales operations.

Since its inception, Obuchi Biotechnology Engineering Co., Ltd. has received the attention of the international biotechnology community. So far, the following results have been achieved: the company's hardware and software platforms have been identified and established, from research and development, production, management to sales, to form a complete technical network of biochips; a complete product standard has been formulated, and the world has also It is the first creation; according to market needs, the company has designed dozens of medium and low density protein chips, and a series of nucleic acid hybrid chips, two types of interactive use, including clinical diagnosis and sanitation and epidemic prevention needs, in addition, and developed supporting Chip identification instrument; the company successfully established a source of raw material supply source, domestic and foreign sources of various high-quality antigens, antibodies, the number of more than 200 kinds, so that the design of a variety of different uses of the chip, become a piece Fully achievable;

The company's visible light identification device has been improved to be both qualitative and quantitative. In addition to reading and analyzing the self-produced chips, it can read the chips that analyze various similar marking methods of other companies in the world, greatly increasing its universality and effectively reducing the cost. The price is only five of the foreign similar products. One of the points, so that the company's visible light recognition instrument becomes a world-class product. At the same time, the company is developing a second-generation chip identifier. In addition to greatly improving the recognition efficiency, it has also added automatic processing systems for chips, reagents and samples. It is expected to be available in July 2003.

Ninth place: Shenzhen Yishengtang Biological Enterprise Co., Ltd.

Yishengtang is a Sino-foreign joint venture established in Shenzhen in May 1994. It is mainly engaged in the production and operation of snake series health care products. It has made great progress in the fields of health care products, proprietary Chinese medicines and bioengineering. Yishengtang has the three production bases of Shenzhen Yishengtang Biological Enterprise Co., Ltd., Shenzhen Yishengtang Pharmaceutical Co., Ltd., Chuangyi Biotechnology Co., Ltd., Shenzhen Yishengtang Pharmaceutical Sales Co., Ltd., and health products, proprietary Chinese medicines and biological products. .

Yishengtang Company has established a nationwide marketing network and a complete sales management system. It has established seven regional sales branches in Beijing, Shanghai, Chongqing, Chengdu, Changsha, Hangzhou and Guangzhou. At present, Yishengtang Company integrates technological advantages, management advantages and talent advantages. While stabilizing the development of health care products and traditional Chinese medicine products, it aims at the broad market prospects of high-tech products, accelerates the research and development of biochip products technology and applications, and strengthens enterprises. ,serve the society.

Eighth: Xi'an Lianer Technology Co., Ltd.

Xi'an Lianer Technology Co., Ltd. is a joint venture established by Xi'an and Beijing. The company is located in the New District Venture R&D Park of Xi'an High-tech Industrial Development Zone. It is mainly engaged in the research and development of clinical diagnostic biochips and their supporting analyzers. Production and sales are among the first companies in China approved by the “National Drug Administration” to apply biochips to human medical diagnosis, and are the first to industrialize and commercialize biochips.

As a world-class high-tech enterprise, Xi'an Lian has the most advanced instruments, equipment and technology in the world. It has strong technical strength in the research of biochips, and dozens of researchers from well-known universities and research institutes across the country. It has formed a high-level R&D team and built a biochip industrialization technology platform, including an antigen-antibody protein manufacturing and purification platform, a genetic engineering bacteria manufacturing and purification platform, a chip production and production platform, a rapid display labeling platform, and a biochip identification platform. On these platforms, we can produce any kind of medical diagnostic biochip.

At present, the company has developed products: biological micro-matrix (chip) analysis system, Helicobacter pylori (HP) detection chip, respiratory disease (RD) detection chip, sexually transmitted disease (Std) detection chip, reproductive tract infection disease detection chip , immunosuppressive disease detection chip, TORCH detection chip, cervical lesion detection chip, M. tuberculosis detection chip, etc.; products under development include: allergy detection chip, myocarditis-related virus detection chip, cervical cancer Early warning chips, etc. The company was also listed as a “high-tech enterprise”, and the “Human Papilloma Virus Research” project jointly developed was included in the national “863 Program”.

The bio-matrix (chip) analysis system of the company is innovative (high specificity, high sensitivity, strong stability), fast (as long as five minutes), and accurate (determinable quantitative) compared with traditional medical testing methods. The characteristics of low price, and a variety of indicators can be detected simultaneously, greatly reducing the suffering of patients. The chip analyzer is a combination of light, electricity, machine technology and modern biotechnology. It can automatically interpret and automatically give test results. It also has report output, patient file management, instrument self-calibration, automatic Internet access and other functions. Stable, easy to operate, the price is only one-fifth of the world's other similar products, very competitive in the market.

Seventh place: Shanghai Boxing Gene Chip Co., Ltd.

Shanghai Boxing Gene Chip Co., Ltd. is a professional chip company under the joint gene technology group. It is one of the largest research and development, production and operation companies of gene chips in China. It is a biochip company integrating high technology and high quality service. Boxing Company can provide a full range of solutions including various biochip products and related technical services. There are more than 30 varieties of expression chip, disease detection chip and commodity inspection chip. China’s first biochip was born in Boxing.

The United Gene Technology Group originated in Fudan University in November 1997. Professor Mao Yumin and Professor Xie Yi led a group of teachers and doctoral and master students from the School of Life Sciences of Fudan University. Starting from 1 million, it has formed a gene technology enterprise group with more than 4 billion assets and more than 30 companies (including two listed companies). In 2007, Bosing introduced a full-scale illumina microbead chip platform, which has provided thousands of chip technical services to hundreds of universities and research institutes at home and abroad.

Sixth place: Shaanxi Chaoying Biotechnology Co., Ltd.

Founded in July 2000, Chaoying Bio has been in business for 14 years. It is a Sino-US joint venture high-tech biotechnology and bioinformatics enterprise that researches, produces and sells biochips and genetic testing. The investment amount is 32 million yuan. At present, the research and development and production management team of more than 50 people, the company has a domestic first-class pathology and molecular biology laboratory and a full set of imported production, research and development equipment and equipment, but also has more than 2,000 square meters of experimental and research sites.

After years of operation, the company has successfully established the first domestic research and development and production base for chip technology and products, and established a number of technology platforms, respectively, and won the “Tenth Five-Year Science and Technology Research Program Western Development Technology Action Major Project” and “SME Innovation Fund”. Projects, “National Key New Products” and other countries and provincial and municipal funds support. He won 4 national invention patents and won the second prize of provincial and municipal scientific and technological progress; the enterprise was also rated as “Xi'an Manufacturing Information Application Demonstration Enterprise”, “Shaanxi Province Introduced Foreign Chile Model Unit” and “Xi'an City Organization” Chip Technology Engineering Center" and successfully passed the high-tech enterprise certification. Chip products and technical services account for 85% of the domestic market share. Since it gradually entered the overseas market since 2003, at present, the products have been exported to more than ten countries and regions such as the United States, Japan, Germany, etc., and have been widely recognized by scientists at home and abroad, thus achieving the leader in organizing chip technology in China. Relative monopoly position.

In 2005, the company began research and development of genetic testing, and established a close cooperative relationship with the cybrdi.us genetic testing center, the world's leading biological research institution. It is the only testing institution with the background of cooperation among multinational authorities in the domestic genetic testing company, and also cybrdi.us. Authorized to be the only frontier base in the Asia Pacific region to engage in the processing and testing of genetic testing samples. At present, our company has an international advanced genotyping technology platform and has been committed to human health and disease research. And the development of "treatment of disease", "children's natural genetic testing" and "high-level genetic testing" three mature genetic testing projects, achieved good results and social repercussions.

In addition to tissue chip products and genetic testing, the company has also developed a series of new products such as in situ analysis kits, molecular biology reagents, cell chips, frozen tissue chips, and diabetes-related autoantibody detection chips.

Fifth place: Shanghai Yulong Biotechnology Co., Ltd.

Shanghai Yulong Biotechnology Co., Ltd. was founded in May 2002 by Dr. Mu Haidong and others, and is mainly engaged in R&D, production, sales and technical services of biochip in vitro diagnostic products (including antigens, antibodies, reagents and instruments). He has applied for more than 110 patents and won several national, provincial and ministerial awards.

The company has a central laboratory in the United States, designing the most advanced technology route, and has a research and development center with international advanced equipment in Shanghai. It has built biochips, automated instruments, biological information, biosensors, genetic engineering, cell engineering, antibody libraries, and proteins. Eight modern biotechnology platforms, such as purification, have advanced equipment such as non-contact biochip spotting instrument, liquid crystal chip workstation, protein purification system, etc., forming a complete molecular diagnostic reagent and its raw materials and supporting equipment research and development, pilot system.

The company independently developed a series of protein chips, gene chips, fluorescent quantitative PCR, enzyme-free, gold-labeled detection kits and supporting automated reaction detection instruments for the diagnosis of major diseases such as hepatitis, tumors and cardiovascular diseases, with high throughput, The characteristics of miniaturization, integration, automation and information technology are sensitive, accurate and fast, and represent the most advanced laboratory medical technology.

The company has a 100,000-level (local 10,000-level) clean biochip production plant and a quality control platform for advanced equipment. The production system is established in accordance with the international ISO13485 standard. The protein chip products and supporting equipment have passed the national SFDA in vitro diagnostic reagents and medical device quality system. Certification, obtained the "Medical Device Business Enterprise License", "Medical Device Manufacturing Enterprise License" and "Medical Device Product Export Sales Certificate".

The company has undertaken the National Engineering Laboratory of Immunodiagnostic Reagents, the 863 Program of the Ministry of Science and Technology, the National Development and Reform Commission, the Biochip High-tech Industrialization Demonstration Project, the Ministry of Health's “AIDS and Viral Hepatitis and other major special projects”, and the Ministry of Industry and Information Industry. The special project, the Electronic Information Development Fund of the Ministry of Information Industry, the special fund for the development of small and medium-sized enterprises of the National Development and Reform Commission, and the National Small and Medium Enterprise Innovation Fund are among the leading projects in the industry.

The company's biochip and instrument projects have also received the attention and support of the national and local governments, and have been included in the “National High-tech Industrialization Specialization” (National Development and Reform Commission), “National Small and Medium Enterprise Innovation Fund” (Ministry of Science and Technology), “National Small and Medium The company specializes in “development of the enterprise” (National Development and Reform Commission), “High-tech Achievement Transformation Project”, “Shanghai Torch Plan”, etc. The company is also recognized as “Shanghai High-tech Enterprise”.

At present, the company is actively carrying out research and development of more sophisticated products and market development of existing products. The company is expanding in scale and is moving towards the goal of an international and comprehensive biomedical enterprise group.

Fourth place: Shanghai Kangcheng Biological Engineering Co., Ltd.

Kangcheng Bio is a high-tech enterprise specializing in the frontier research technology of life sciences. It is committed to promoting the application, development and innovation of advanced international molecular biology technology in scientific research.

Kangcheng Bio's products and technical services cover many research fields in life sciences, including genomes, epigenomes, transcriptomes and proteomics. It has built a number of technical service platforms for researchers: [Biochip technology platform] microRNA chip, long Chain non-coding RNA chip, expression profiling chip, DNA methylation chip, ChIP-chip, aCGH, protein chip, etc. [Illumina GA IIx second generation high-throughput sequencing platform] microRNA sequencing, chromatin immunoprecipitation sequencing, DNA Methylation sequencing, transcriptome sequencing, and the like.

Kangcheng Life Science Experimental Center has first-class experimental equipment, experienced experimental technical team and bioinformatics engineer team to provide technical services and create scientific research value for professional scholars with professional knowledge and excellent service. In the past five years, Kang Cheng Bio's products and services have covered the Chinese Academy of Sciences, the University of Hong Kong, Tsinghua University, Peking University School of Medicine and Affiliated Hospital, Sun Yat-sen University School of Medicine and Affiliated Hospital, Shanghai Jiaotong University School of Medicine, Ruijin Hospital, Fudan University School of Medicine Zhongshan Hospital, Huazhong University of Science and Technology Tongji Medical College affiliated hospital, Novartis (Nova), gsk (GlaxoSmithKline) and other domestic first-class research institutes, medical institutions and multinational pharmaceutical groups, providing technical services and cooperation for more than 5,000 domestic customers. About 70 SCI articles have been published, including the top international journals Nature Medicine, Nature Genetics, Circulation, Oncogene, etc., which are in the leading position in the same industry!

Third place: Tianjin Biochip Technology Co., Ltd.

Tianjin Biochip Technology Co., Ltd. (TBC) was established in September 2003 and was jointly funded by Tianjin Zhongxin Pharmaceutical Group Co., Ltd., Nankai University, Tianjin Venture Capital Co., Ltd., and Tianjin Economic and Technological Development Zone State-owned Assets Management Company. Mainly engaged in the research and development of microbial detection chips, genomics and functional genomics research. The company is one of the five biochip R&D bases funded by the National 863 during the Tenth Five-Year Plan period, and is the only base dedicated to the research and development of biochips for pathogenic microorganisms. The company has a complete set of core technologies in the screening of microbial detection specific molecular markers, and has established a multi-disciplinary platform representing the world's most advanced biological research and development and industrialization in the field of microbial detection biochip technology. The field of genomics and functional genomics research is at the international advanced level. The company is a high-tech enterprise recognized by Tianjin (Certificate No.: 0412007B5018); in January 2005, it was approved by Tianjin Municipality to establish Tianjin Functional Genomics and Biochip Research Center; in June 2006, it was approved by the Ministry of Education to establish a microbial functional genome and Testing Technology Engineering Research Center of the Ministry of Education.

Tianjin Biochip Technology Co., Ltd. is located in Tianjin Economic and Technological Development Zone with a registered capital of 100 million yuan and a total construction area of ​​4,800 square meters, including a laboratory area of ​​3,800 square meters. It has established a complete public laboratory system in accordance with internationally accepted standards. It includes four research platforms: genomics, functional genomics, bioinformatics and biochips, forming a multidisciplinary, open modern biotechnology research platform. At present, an international level innovation team consisting of 108 people has been established. There are 8 academic leaders in the field, all of whom have long-term experience in studying and working abroad.

Since its establishment, the company has undertaken 13 scientific and technological projects including Tianjin Science and Technology Innovation Special Fund, established a development model of combining production, learning and integration, and formed a market-oriented, technology-based operating mechanism. Established a platform for the industrialization of scientific research results. The company has undertaken a large number of major scientific research projects at the national and provincial level, such as the “863 Program” and the “National Science and Technology Support Program” during the 15th and 11th Five-Year Plan period. It has published SCI in the top international journals such as Nature and PNAS. More than 130 papers have been included, which has established a leading position in the field of biotechnology and international advanced status. The most representative of these is that the company and the University of Hawaii co-hosted a large-scale international cooperation program, the “Papaya Genome Project”, which was published on April 24, 2008 in the most authoritative and influential British journal of nature. Published as a cover article. This is the first time that the scientific community in Tianjin has published a cover article in the journal Nature. It is also the third time in China that the scientific field has published a cover article in the magazine since 2000. At present, the company has mastered the core technology of screening DNA-specific molecular markers from gene families encoding bacterial surface antigens, and established the largest microbial-specific molecular identification library in the world, which has reached the international leading level in this field and obtained 2 US invention patents and more than 100 domestic invention patents.

In terms of technical services, the company has established a strategy of actively developing the technical service market based on four research platform systems such as genomics and the establishment of awareness and influence in the field of biotechnology through a large number of scientific research results. Services include genomics, proteomics, biochips, bioinformatics, microbial identification, polyclonal antibody customization, etc. There are 68 items in 6 major projects, covering customers in Beijing, Tianjin, Wuhan, Shenzhen, Kunming, Hong Kong and other cities. surrounding area.

In terms of product development, the company provides microbiological testing solutions for different testing sites, different testing objects, different fluxes, and different types of laboratories according to customer needs: including sample preparation, immunological detection, molecular biology testing, and data analysis. In various aspects, 85 kinds of products including diagnostic serum, immunomagnetic beads and molecular biological detection kits have been developed.

Second place: Boao Biological Co., Ltd.

Boao Bio-Group Co., Ltd. and Biochip Beijing National Engineering Research Center ("Boao Bio-") on September 30, 2000 in the State Council, the National Development and Reform Commission, the Ministry of Science and Technology, the Ministry of Education, the Ministry of Health and Beijing leaders care and support Under the support of Tsinghua University, the Huazhong University of Science and Technology, the Chinese Academy of Medical Sciences, the Academy of Military Medical Sciences was incorporated. Its predecessor was the Biochip Research and Development Center of Tsinghua University. The registered capital is 376.5 million yuan, with 65,000 square meters of research and development, production, operation and service facilities. In 2014, Boao Biotech formed three research institutes (Transformation Medicine Research Institute, Engineering Transformation Research Institute, Health Science Research Institute) and four subsidiaries (Beijing Boao Jingdian Biotechnology Co., Ltd., Beijing Boao Medicine). The Group's operational structure of the Institute, Boao and Health Science and Technology (Beijing) Co., Ltd. and Boao Muhua Gene Technology Co., Ltd.

As one of Tsinghua's member companies, Boao Bio is committed to developing and delivering innovative technology products and services for life sciences and integrated medical (including predictive, preventive and personalized medicine). Innovative technologies have successfully developed five series of dozens of products and services with independent intellectual property rights, including biochips and related reagent consumables, instruments and equipment, software databases, life science services, and clinical testing services. More than ten of them are international initiatives. More than 200 patents have been granted worldwide. The development and application of its systematic biochip and related instruments and equipment won the second prize of the 2007 National Technology Invention Award. In 2008, the National Biochip Standardization Technical Committee (TC421) was established in Boao Bio. As the chairman of the National Biochip Standardization Committee and the secretariat, Boao Bio actively participates in and promotes the standardization of biochip technology in China. A number of national standards and clinical diagnostic industry standards have been approved. In May 2009, the Chinese Hematopoietic Stem Cell Donor Database Library (referred to as the “China Marrow Library Sample Library”) was built in Boao Bio. In the same year, the crystal core confocal scanner LuxScanTM10K was awarded the first batch of “National Independent Innovation Products” by the Ministry of Science and Technology. In January 2010, Boao Bio was approved by the State Intellectual Property Office as a national IPR pilot unit. In September 2013, Boao Biological Subsidiary Beijing Boao Medical Laboratory Co., Ltd. became the first batch of individualized medical testing pilot units set up by the National Health and Family Planning Commission. It undertakes the verification and revision of relevant management methods and technical guidelines for personalized medical testing. , improve and summarize and other work. Boao Bio has also supported hundreds of research papers published in internationally renowned journals such as Science, Cell, Nature Genetics, and NatureBiotechnology by providing various biochip technology services.

First place: Shanghai Biochip Co., Ltd.

With the development of society and the advancement of science and technology, people pay more and more attention to health care, and most of the health-related diseases are closely related to their own genetic and living conditions. For such diseases, they must be tested at the genetic level and then controlled. Biochip technology is a high-throughput biomolecular level detection system that combines the achievements of modern science and technology. It not only provides a powerful tool for life science research and drug research and development, but also can be applied to modern health care systems, serving people's health-related prevention, prediction and personalized treatment, as well as food and epidemic detection.

In the context of international biochip technology and industrial development, Shanghai Biochip Co., Ltd. was established in August 2001. The company's main business is biochip technology innovation and service, product development, production and sales. The company is committed to the application and promotion of biochips in the fields of life science research, health care, food safety and drug development, for the benefit of human health. The company is composed of 11 well-known domestic universities, research institutes, hospitals and enterprises in Shanghai, including Shanghai Venture Capital Co., Ltd. and Shanghai Institute of Life Sciences of Chinese Academy of Sciences.

In February 2003, the National Development and Reform Commission approved Shanghai Biochip Co., Ltd. to be responsible for the construction and operation of the “Biochip Shanghai National Engineering Research Center”. The purpose of the construction and development of Biochip Shanghai National Engineering Research Center is to promote the research and product development of biochip technology in China, promote the development of biochips and related technologies and industries, provide technical platform support for the industry, and cultivate talents in the biochip industry. It is part of the national innovation system, represents the development direction of the industry, has the ability to create independent intellectual property rights, promotes the relevant industrialization process, reflects the will of the state, and undertakes the scientific and technological tasks of major national priorities. At the same time, it is an independent enterprise that must establish the ability to survive independently, develop itself, and be able to withstand the risks of wind and waves in the market. Under this guiding ideology, develop the development strategy and planning of the company (center).

The company (center) takes "scientific research and innovation, market orientation, and people-oriented" as the core value of the company, guided by technology and product research and development, with enterprise operation as the operating mechanism, and internationalization of products, markets and technologies as the standard to build To become a "first-class molecular biology detection technology platform, research and development and production series of testing products" as the goal, combine modern enterprise system and innovation-oriented scientific research mechanism to create a company (centre) culture that is brave to explore, actively innovate and practice hard. In an effort to build a world-renowned, domestically leading biotechnology company with biochip technology business characteristics.

The company's (center) development strategy is positioned to: establish and strengthen the competitive advantages of functional genomics and pharmacogenomics research, translational medicine and biochip integrated technology platforms, integrate technology, capital and human resources through self-management and capital operation methods to create and The three main businesses of the development of scientific research and results application transformation, molecular and health diagnostic products and technical service outsourcing business of drug research and development, using the "combined fleet" business model, forming a chip company as the flagship, each holding subsidiary is a professional ship , a joint fleet of biomedical technology group companies.

According to the company (central) development strategy, the specific planning forms several major modules of the company's business: technical services and R&D outsourcing business based on the holding subsidiary Shanghai Bohao Biotechnology Co., Ltd.; Sino-US joint venture Shanghai Yingboken Biomedical Company The business segment of the research, development, production and sales of medical clinical diagnostic test products jointly formed by Huaguan Company and Xinchao Company and Southern Gene Company.

Source: OFweek Electronic Engineering Network

6g Medical Nitrile Gloves

We, Jiangsu YanFang Medical Technology Co., Ltd, commenced our medical gloves manufacturing in 2020. Currently, we possess a total of 12 high-capacity NBR Glove Dipping Production Lines.
Likewise, we are not only certified with ISO9001, ISO13485 but also fully complied with the essential USFDA, CE Compliances, as well as obtaining relevant accreditation of FDA510K, EN455, and EN374.
Nonetheless, our NBR Examination, Chemotherapy, and Food Grade products are being well established in both US and Europe markets.
We look forward to cooperating and working closely with our valuable customers and stakeholders, who are seeking long-term business relationships in high-quality NBR glove supplies.

Medical Examination Nitrile Gloves,Disposable Nitrile Gloves,Medical Safety Nitrile Gloves,Exam Gloves

Jiangsu Yanfang Medical Technology Co.,Ltd. , https://www.yanfangchina.com